Clinical effect of Carapacis Trionycis Bolus treating hepatitis cirrhosis
LI Heng-fei1 YAN Deng-ying2 XU Jian1 CHEN Qin1
1.Department of Hepatology,Hubei Provincial Traditional Chinese Medical Hospital,Wuhan 430074,China;
2.Graduate School,Hubei University of Traditional Chinese Medicine,Wuhan 430061,China
Abstract：Objective To explore the clinical effect of Carapacis Trionycis Bolus treating hepatitis cirrhosis.Methods A total of 86 patients with hepatitis cirrhosis treated in Hubei Provincial Traditional Chinese Medical Hospital from February 2013 to February 2017 were selected as the study subjects,and they were divided into the the control group(n=43)and observation group(n=43)according to the order of medical treatment.The control group was treated by routine western medicine,mainly using Entecavir Dispersible Tablets,while the observation group was treated by combined method:Entecavir Dispersible Tablets+Carapacis Trionycis Bolus.HBV-DNA negative condition,liver function index and liver fibrosis before and after treatment were compared between the two groups.Results The negative rate of HBV-DNA was 44.19%in the 12thweek,and it was 58.14%in the 24th week and 93.02%in the 48thweek in the observation group,which was higher than that of the control group (25.58%,32.56%,48.84%)respectively,and the differences were statistically significant(P＜0.05).There was no significant difference in the levels of STB,ATL and ALB before treatment between the two groups(P＞0.05),after treatment,the levels of STB and ATL were lower than those before treatment,and the levels of ALB were higher than those before treatment in the two groups,and the differences were statistically significant(P＜0.05),after treatment,the levels of STB and ALB in the observation group were higher than those in the control group,and the level of ATL was lower than that in the control group (P＜0.05).There was no significant difference in the levels of CL-Ⅳ,PCⅢ,LN and HA before treatment between the two groups(P＞0.05).After treatment,the levels of CL-Ⅳ,PCⅢ,LN and HA in the two groups were significantly lower than those before treatment,and the differences were statistically significant(P＜0.05).The levels of CL-Ⅳ,PCIII,LN and HA in the observation group were lower than those in the control group after treatment,and the differences were statistically significant(P＜0.05).Conclusion Carapacis Trionycis Bolus treating hepatitis cirrhosis can inhibit HBV-DNA polymerase to a certain extent,reduce HBV replication,alleviate liver inflammation and fibrosis,reduce the incidence of canceration and complications,clinical effect is satisfactory,and it is worthy of further promotion and application.
Wang FY，Li B，Li Y，et al.Entecavir for patients with hepatitis B decompensated cirrhosis in China：a meta-analysis[J].Sci Rep，2016，6：32 722.
[2]
Huang R，Wang J，Zhao XA，et al.The impact of cirrhosis on the efficacy and safety of entecavir for patients with chronic hepatitis B[J].Eur J Gastroenterol Hepatol，2017，29（11）：1314.
京公网安备 11010502046607号